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Background and rationale
Since Looney at al. published their seminal paper a dec-
ade ago [1] it has become clear that many of the differ-
ences in T cell immunological parameters observed
between young and old people are related to the age-
associated increasing prevalence of infection with the
persistent b-herpesvirus HHV-5 (Cytomegalovirus). Ten
years later, studies suggest that hallmark age-associated
changes in peripheral blood T cell subset distribution
may not occur at all in people who are not infected
with this virus [[2]; Derhovanessian et al., in press].
Whether the observed changes are actually caused by
CMV is an open question, but very similar, rapid
changes observed in uninfected patients receiving CMV-
infected kidney grafts are consistent with a causative
role [3]. This meeting intensively discussed these and
other questions related to the impact of CMV on
human immune status and its relevance for immune
function in later life.
A more difficult question to answer is whether age-
associated immune changes believed to contribute to
the immunodeficiency of ageing are likewise caused by
CMV. This seems a priori unlikely because CMV infec-
tion is very widespread, yet very elderly CMV-seroposi-
tive individuals are easily identified (although formally it
is impossible to exclude that they were only recently
infected). Thus, an important question becomes whether
the CMV-sensitive altered immune cell subset distribu-
tions in the elderly, particularly the decreased numbers
and percentages of naïve T cells and increased late-stage
differentiated memory T cells (commonly used as bio-
markers to assess “immunosenescence”), are in reality
an epiphenomenon irrelevant for predicting health
status in very old people. In order to discuss these and
other relevant questions, a workshop was organised at
the Center for Medical Research in Tübingen in Decem-
ber 2009, attended by virologists, immunologists and
geriatricians whose brief was to elucidate the important
questions on this issue, and make a first attempt at
answering them. Questions focussed on the mechanisms
of age-associated alterations to immunity, how far these
alterations can be ascribed to CMV infection, and
whether and to which degree other sources of “chronic
antigenic stress” (eg. cancer, parasite infection, amyloid-
b, other viruses, autoantigens) may be additive with
CMV in this respect. The crucial question of how far
we are able to assess the clinical impact of these factors
using epidemiological approaches, longitudinal and
cross-sectional studies was to be discussed, as well as
the mechanisms responsible for such outcomes. The
clinical relevance and predictive value of establishing
immune signatures influenced by the above factors, in
terms of longevity, cause of death, responsiveness to
vaccination etc. must be established in order to make
informed plans for translational work. Bearing this in
mind, as well as the thus-far equivocal data on associa-
tions between mortality and CMV-seropositivity as a
single factor, specifically, the questions which the parti-
cipants tried to answer in this workshop were as dis-
cussed below. The number of important questions and
paucity of anything approaching clear answers to most
of them emphasizes the dire need for intensive investi-
gations in this important area (Table 1).
• What is immunosenescence?: how to define it:What are
its immune signatures?
First, the exact meaning of the term “immunosenes-
cence” was considered. A consensus view could be
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stated as follows: Immunosenescence is the impairment
in immunity as a result of age-associated changes in
function in a variety of cells: it is a phenomenon of
decreased function, involving changes to both innate
and adaptive immunity and a dysbalance between the
two arms. Immunosenescence needs to be investigated
not only in cells from the peripheral blood, but in tis-
sues as well (easier said than done in humans). Any
identified age-associated changes, if to be considered
senescence, or “immune frailty”, must be shown to con-
tribute to deleterious clinical endpoints, such as
decreased efficacy of vaccination in the elderly, for
which there is some evidence (influenza, tuberculosis).
This defect could stem from immune deficiency but also
from defects at the site of vaccination (muscle) as well
as cell recruitment (ie. in the interactions between aged
tissues and components of immunity). A decreased abil-
ity to respond to pathogens in general is implied. All
these points seem fairly obvious, but few have been
well-investigated in appropriate studies. Hence, the gen-
eral conclusion was that we need better markers for
immunosenescence, and more data on its actual clinical
relevance. There are many candidate markers but most
of the correlations between such markers and any clini-
cal endpoint remain largely hypothetical and in fact still
require confirmation. Moreover, it was felt that many
other factors, such as genetics, nutrition, stress, co-mor-
bidities and socioeconomic factors are important in
determining immunosenescence and clinical outcome,
but that these have not yet been properly accounted for.
• Relevance of the immune risk profile, IRP: general
applicatibility? How do we measure it?
The concept of an “immune risk profile” (IRP) estab-
lished from longitudinal studies of very elderly people in
the southern Swedish city of Jönköping, did not investi-
gate any correlations of immune parameters with
response to vaccination. Instead, the IRP was defined
solely in terms of mortality as a cluster of parameters
including increased numbers of late-differentiated CD8
cells (but NOT decreased numbers of naïve CD8 cells)
as well as low B cells: and CMV seropositivity [4,5]. The
IRP was defined at baseline in 85 year-olds (note that
even at 85 years, only ca. 15% of subjects are in the IRP
group), with 2, 4 and 6 year follow-up. All people in the
IRP group were CMV-seropositive, compared to around
85% in the non-IRP group.
The concept of the IRP is being applied to many
different populations, but it is not clear whether this is
appropriate. So far, as outlined above, we only know
that it applies to very elderly Swedes from the town of
Jönköping. Although there is a priori no real reason to
suspect that other populations may differ, this is merely
an assumption. Moreover, even in Sweden, we don’t
know at what age the IRP becomes relevant; very preli-
minary data suggest that it might start to be associated
with excess mortality after age 65, but not at 55 [6].
Although longitudinal studies such as these are crucial,
they remain rare, and practical considerations dictate
that much of the available data in humans is and
will remain derived from cross-sectional studies.
It was therefore considered of great importance to pur-
sue these types of longitudinal studies in diverse
populations.
Whichever type of study is carried out, it was agreed
that standardized multiparameter measurements are
necessary, to be combined with factors not overtly
immunological, ie. biological, functional and cognitive
markers of ageing (including ADL, IADL, MMSE, GDS).
If not using mortality as a robust but perhaps less than
optimally informative endpoint, what clinical parameters
can be utilised to assess the impact of immunosenes-
cence? The above-mentioned functional tests could be
good endpoints in elderly subjects. The assessment of
the association between IRP and clinical frailty should
be also considered as an endpoint. Skin testing (DTH
reactions) would be a good endpoint, and is very differ-
ent in young and old people. It is simple, ethical and
cheap, but might reflect skin ageing more than immuno-
senescence directly. The response to vaccination would
be another obvious end-point. However, it must also be
borne in mind that recall responses can be less affected
in the elderly, and that primary vaccination, eg. to a
new strain of flu, may be difficult. For Zoster, whatever
the humoural responses in the elderly, the reactivation
of the virus is directly linked to decreased T-cell
response levels that lead to the clinical problem. It was
also suggested that simple in vitro functional studies
Table 1 CMV and Immunosenescence: more questions than answers
Innate immunity Adaptive immunity CMV Clinical endpoints
CD4 CD8 B cells
Immunosenescence altered altered altered altered present ?
IRP ? altered altered altered present death
Frailty ? ? ? ? present disability
Vaccination ? altered altered altered present ?
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might act to some extent as a surrogate, eg. the TNF
response in whole blood to stimulation with LPS as a
marker of general functionality (proliferation in the
whole blood can be also considered). This should be
easy to do, and is well-standardised.
How does CMV itself contribute to morbidity/mortality?
What are the reactivation patterns of CMV, and does this
occur more frequently in the elderly?? Is CMV reactivation
an overlooked occult clinical problem at the end of life?
As discussed above, the presence or absence of CMV
infection is one of the factors clustering with others to
give the IRP in the very elderly. A major area for discus-
sion at this workshop concerned the mechanisms
responsible for this association. The main causes of
death in the Swedish studies were infection and heart
failure. One of the relatively less controversial findings
regarding CMV and health status is the association with
atherosclerosis and heart disease, where recent data
have also indicated that not only CMV infection per se
but the titer of anti-CMV antibody in the patient may
correlate with survival time [7]. Thus, in all considera-
tions of the impact of CMV on any measured para-
meter, it will be necessary to determine IgG antibody
titers; it will also be informative to measure IgM, as well
as antibody avidity and possibly specificity for the multi-
ple CMV epitopes recognized by antibodies present in
infected people. Given these provisos, and the near-ubi-
quity of CMV infection, it is not surprising that correla-
tions between the mere fact of CMV infection and
mortality are hard to establish.
An important question remains whether time of infec-
tion with the virus can be reflected in a more sophisti-
cated serological analysis, as alluded to above. This is
currently unknown. It is also unclear whether some
individuals are simply more competent at controlling
CMV and invest less resources in having to do so, with
a possible ensuing advantage in later life. There is some
preliminary data in familial longevity that this may be
the case. The nature, profile or pattern of the CMV-
response is likely to be more important than mere sero-
positivity. Patterns of anti-CMV antibody response in
the young are very stable. Immediately after primary
activation a full-blown response to every antigen is seen,
which then decreases: IE1 is the first to decrease, pp150
persists over a longer time (IgM reactivity). Some IgM
Abs persist for over 2 years but patterns can change
during latency. For IgG, both specificity and quantity
remain stable. Although IgG testing is very robust, there
is no international standard for CMV Ab levels. All
these aspects require attention.
CMV may also cause pathology by reactivation but we
do not know how frequently CMV reactivates asympto-
matically in the elderly, and if this is more frequent
than in the young, whether it matters. Although
geriatricians have a strong feeling that CMV end-organ
disease is not a clinical problem in the elderly, by con-
trast with immunodeficiency syndromes where retinitis,
or colitis may be clinically apparent, this might have
been overlooked. So, for example, could bacterial pneu-
monia as a likely proximal cause of death actually follow
occult CMV pneumonitis? Alternatively, the major
impact of CMV might be indirect, perhaps by contribut-
ing to a low-level pro-inflammatory state, which is asso-
ciated with frailty in the elderly [8].
Stress and inflammation also tend to activate CMV,
but immunosuppression alone is not enough for reacti-
vation; it seems that TNF is needed and NF-B signal-
ling is also important. So, will the low level pro-
inflammatory status in the elderly lead to more reactiva-
tion? Is this potentially a vicious circle? Elderly people
who become infected with the virus at old age from
their grandchildren may well end up in the hospital
with acute CMV infection, but this does not seem to
happen otherwise. Hence, functional protection does
appear to be well-maintained; CMV-specific immune
responses are very heterogeneous and there is probably
a great deal of redundancy in this crucial defence
mechanism. It is believed that pp65 and IE1 are equally
good in controlling CMV spread in transplant patients,
but pp65-specific T-cells can sometimes be protective,
sometimes not. There is also a notion that pp65 may be
a decoy antigen, a way of evading the immune response
of the host.
CMV and immune phenotype. What is the significance of
the immune signature of CMV?
The biggest impact of CMV infection on immune para-
meters is to drive the accumulation of late-stage differ-
entiated CD8+ T-cells, a prime characteristic of the
Swedish IRP where increased absolute numbers and per-
centages of CD8+ CD27- CD28- cells contributed to the
inverted CD4:8 ratio and poor proliferative responses,
representing the major difference distinguishing the
higher risk group from the rest of the population.
CMV-specific CD8 clonal expansions have a low turn-
over and fail to apoptose readily. However, whether
these cells are deleterious or necessary for the host is
unclear. Despite the concept of the finite immunological
space, and the idea that these cells might “crowd out”
others, there is little actual evidence that this does occur
or, if it does, whether it is clinically relevant. Within
these accumulated late-stage memory cell populations,
repertoire narrowing might be important, besides prolif-
erative senescence, apoptosis resistance and functional
exhaustion (as implied by the very small and not-yet
replicated study carried out on the Swedish sample, see
ref. [9]). Such CD8 cells of different functional status
(senescent-vs-non-senescent?) might be distinguishable
by virtue of their expression of receptors like PD-1 or
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KLRG-1. However, each of these markers alone will
probably not be sufficient to subdivide them, because,
for example, KLRG1+ T-cells can have just as good a
cloning efficiency as KLRG-1-negative cells if costimu-
lated with 4-1BB. Probably no cell type is totally dys-
functional; this raises the question as to whether any is
truly “senescent”. It was concluded that this crucial
question remains open.
Despite the widespread belief that decreased numbers
of naïve cells in the elderly must be a bad thing, and the
certainty that CMV infection drives down the numbers
of such cells even further, whether this parameter is
actually associated with a measured clinical outcome has
not been properly tested in humans. One way of testing
this would be to assess primary responses to neoanti-
gens. Yellow fever vaccine may be a suitable example;
however because it induces such strong responses,
impairment in elderly cohorts may be difficult to mea-
sure. Less strongly stimulatory vaccines may be more
revealing.
If CMV has such an over-riding effect on immune sig-
natures, are there likely to be any additive effects of
other viruses, pathogens or different sources of “chronic
antigenic stress”. There is some evidence that EBV has a
minimal effect in addition to CMV, but that VZV and
HSV do not. In other conditions such as rheumatoid
arthritis, Alzheimer’s Disease, and prostate cancer, there
is some evidence consistent with CMV exacerbation; the
same may be true of serious psychological stress. Evi-
dence is sparse, but what is there suggests that there
may indeed be additive immune “exhausting” effects of
polypathologies.
Characteristics of immunosenescence and the IRP?
Many detailed questions were formulated in order to
provide a framework for discussing the crucial gaps in
knowledge concerning CMV and immunosenescence.
These included asking whether immunosenescence
starts at the level of the hematopoietic stem cell (HSC);
the role of the thymus? Which biomarkers are best?
What impact does CMV have on the HSC microenvir-
onment, thymus? Is there no age-associated decrease of
CD8 naïve cells in CMV-negative people? Is the
decrease in naïve cells in CMV+ people limited to CD8,
and not CD4, cells? Is the decrease of naïve cells asso-
ciated with any clinical outcome? Are T-regs altered
with age and what is the effect of CMV thereon? Does
CMV affect B cells (part of the IRP)? Is there a contri-
bution of innate immunity to the IRP? What is the
impact of CMV on cells bridging innate and adaptive
immunity (Th17, Tgδ, NK, NKT, DC)? What is the rele-
vance of telomere length measurements? Relevance of
humoural factors, cytokines, such as type I IFN blocking
telomerase; CMV induces type I IFN, and feedback will
have to be established. Systems approaches will need to
be invoked for a full understanding of these interactions.
Regarding the impact of CMV on HSC, it now seems
clear that most cell types can be infected, not just mye-
loid and endothelial cells. Although immediate early and
late genes are not expressed in CD34+ HSC, two pro-
teins are candidates for latency-associated viral products,
and RNA has been detected in stem cells. However, only
a small proportion of stem cells seems to be infected, so
the effect of CMV on HSC is probably negligible. On
exiting the bone marrow, T cell progenitors must be
processed in the thymus. Despite the well-known but
nonetheless still little-understood phenomenon of age-
associated thymic involution, even the very elderly com-
monly seem to retain some residual thymic function. Is
thymic output different in CMV+ and CMV- indivi-
duals? This was felt to be an important question to
answer, too. Given the difficulty in identifying naïve
cells in the elderly, this may not be so easy as would
appear at first sight. How should we define naïve cells?
Telomere lengths and TRECs are probably the best way,
but patterns of cytokine production and surface markers
CD31, LFA1 should be assessed as well.
Another area of great topical interest concerns Tregs:
their frequency appears to increase with age but the
impact of CMV on these cells is only just beginning to
be studied. The frequency of Foxp3 expression appears
similar in clonal expansions of CMV-specific T-cells and
total CD4+ T-cells and the frequency of Tregs is similar
in CMV+ and CMV- individuals. Of course, more subtle
changes in Treg subpopulations or functional changes
may be significant. Do Tregs make the virus reactivate
more or less? Similarly, are there any CMV-specific
Th17 cells and do they differ between young and old?
There was also much discussion on components of
the innate immune system, CMV and immunosenes-
cence. It was noted that gδ-T cells expand after CMV
infection in transplant models, but very little has been
described concerning these cells in ageing, and the
impact of CMV. Similarly, although of great importance
in CMV immunosurveillance, and probably also in
immunosenescence, the impact of NK cell status on
morbidity/mortality in the elderly is very much an open
question. It was noted that low NK cytotoxicity may
predict cancer recurrence, as well as infectious disease
susceptibility in later life, but, again, data are very
scarce. NKT cells are also likely to play some role in
this respect. There may be enrichment of a certain type
of NK cell accumulating in CMV+ individuals, and
these also grow out of peripheral blood cells when
cocultured with CMV-infected fibroblasts. Some rather
subtle changes to DC and antigen presentation have
also been noted in ageing, and antigen presentation is
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known to be decreased in CMV+ individuals. This also
needs clarification in the context of immunosenescence.
Neutrophils can also be infected by CMV and their role
in chronic viral infections, especially reactivation, also
requires attention.
Could there be an early-life or any other benefit from being
infected with CMV?
Finally, it was considered whether there is any evidence
for beneficial effects of CMV, helping to explain its
unique interactions with immunity and the inability of
the host to eliminate the virus? For example, cells
expanded in CMV+ patients may protect against cancer,
as there is some evidence for lower cancer rates in
CMV+ individuals. Other advantages from CMV-infec-
tion might be reduced allergies or infections in early
life, due to the increased proinflammatory status of
infected people. Less alloreactivity and hence organ graft
rejection may be seen in patients with high levels of
some CMV-specific T cells [10].
• Interventions? Should we try to suppress CMV?
The overall feeling was that CMV is bad for you. On
balance, its elimination was thought to be desirable.
Vaccination is one option, and the first report recently
of a vaccine for preventing acquisition of primary infec-
tion by seronegative mothers is encouraging [11]. Thera-
peutically, vaccination in CMV+ individuals might be
able to boost antibody responses. However the logic of
this approach depends on inducing a different type or
scale of immune response to that induced by natural
infection, which we know does not achieve clearance of
CMV from infected individuals, and not from lack of
magnitude. Vaccine trials are ongoing. In the case of
VZV therapeutic vaccination, 50-60% reduction of Zos-
ter incidence in the treated group has been attained,
making it conceivable that something similar might be
achieved for CMV. Other approaches are certainly pos-
sible, but the question remains: if we get rid of CMV
what will be the impact?
At the end of this First International Workshop on
CMV & Immunosenescence, the attendees decided that
it would be extremely valuable to repeat the exercise in
a year’s time in order to update participants on progress,
include areas and experts omitted from or unable to
attend the first workshop and identify new areas of
investigation. To this end, the Second International
Workshop on CMV & Immunosenescence will be held
in Cambridge, UK, 2-4th December, 2010, organised by
Mark Wills.
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